AbbVie Seeks Section 337 Import Ban on Humira Biosimilar
AbbVie seeks a ban on imports of adalimumab biosimilars from Alvotech, Teva and Ivers-Lee that allegedly rely on misappropriated trade secrets, it told the International Trade Commission in a Section 337 compaint filed Dec. 17. AbbVie says the companies seek…
Sign up for a free preview to unlock the rest of this article
Export Compliance Daily combines U.S. export control news, foreign border import regulation and policy developments into a single daily information service that reliably informs its trade professional readers about important current issues affecting their operations.
to bring to market a biologic called AVT02, which is similar to AbbVie’s Humira brand adalimumab, used to treat a variety of conditions such as rheumatoid arthritis, Crohn’s disease and ulcerative colitis. AbbVie seeks a limited exclusion order and cease and desist orders against AlvoTech, Teva and Ivers-Lee. Comments are due to the ITC Jan. 3.